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PROSTATE CANCER DETECTION, CHARACTERIZATION, AND
CLINICAL OUTCOMES IN MEN AGED 70 YEARS AND
OLDER REFERRED FOR TRANSRECTAL ULTRASOUND AND
PROSTATE BIOPSIES
JEFFREY C. SUNG, JOHN N. KABALIN, AND MARTHA K. TERRIS
ABSTRACT
Objectives. To evaluate the diagnostic findings and treatment options chosen in men aged 70 years and
older referred for prostate biopsy.
Methods. Age, prostate-specific antigen (PSA), biopsy pathology, clinical stage, treatment pursued, and
treatment outcome were analyzed in 210 men age 70 years and older referred for transrectal ultrasound and
prostate biopsies. All patients were followed for a mean of 46.9 months (range 28 to 63).
Results. Cancer was found in 120 (56.8%) of the patients. The cancer detection rate was significantly higher
(81.0%) in patients aged 80 years and older than those younger than 80 years. Cancer patients aged 80
years and older had a higher rate of poorly differentiated cancer (64.7%) compared with the 70 to
74-year-olds (33.3%) and 75 to 79-year-olds (32.1%). The patients aged 80 years and older also had a
larger proportion of high-stage cancer. The patients younger than 80 years had a significantly higher
incidence of stable/falling PSA with treatment compared with the older patients. Of the 210 patients, 41
(19.4%) died within 5 years of the diagnostic procedure; 3 died of prostate cancer. The death rate was not
significantly different among the three age groups evaluated. None of the patients aged 80 years and older
died of prostate cancer.
Conclusions. Patients aged 80 years and older who are diagnosed with prostate cancer are less likely to
respond well to treatment and usually die of unrelated causes. Aggressive diagnosis, staging, and treatment
in octogenarians should be guided by the patients’ symptoms, overall health, and personal
preferences. UROLOGY 56: 295–301, 2000. © 2000, Elsevier Science Inc.
The Prostate Patient Outcomes Research Team(PPORT) reported the national Medicare ex-
perience with prostate cancer treatment outcomes
in 1993, concluding that aggressive treatment of
prostate cancer in patients aged 70 years and older
was generally harmful.1 Subsequent treatment
trends have shown a dramatic drop in the number
of patients aged 70 years and older who undergo
radical surgery.2 Even the aggressive evaluation for
the presence of prostate cancer in men aged 70
years and older is discouraged because treatment
options are limited.3 However, in clinical practice
many men in this age group present for evaluation
and counseling. We retrospectively reviewed the
presentation and clinical outcome in 210 consecu-
tive men aged 70 years and older who were referred
by urologists for transrectal ultrasound and ultra-
sound-guided prostate biopsy in the 3 years follow-
ing the PPORT recommendations.
MATERIAL AND METHODS
From March 1, 1994 to February 28, 1997, 210 men aged 70
years and older were referred to the urology clinic of the Vet-
erans Affairs Palo Alto Health Care System for transrectal ul-
trasound and ultrasound-guided prostate biopsies. The men
ranged in age from 70 to 88 years (mean 74, median 74). In all
patients, serum for determination of prostate-specific antigen
(PSA) level and digital rectal examination were obtained prior
to the procedure.
PSA levels before biopsy ranged from 0.4 to 564 ng/mL
(mean 23.3, median 9.4). Transrectal ultrasound and ultra-
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sound-guided biopsies were performed in all patients by the
systematic sextant method previously described.4 Additional
directed, transition zone, or seminal vesicle biopsies were per-
formed when clinically indicated.5–8 The average number of
biopsies taken was 8 (range 6 to 13). Biopsy specimens from
each of the sites were labeled and submitted separately for
histologic analysis. Each specimen was fixed in 10% formalin,
embedded in paraffin, sectioned longitudinally, and stained
with hematoxylin and eosin. Each biopsy core was carefully
examined microscopically for the presence of cancer. For each
patient, the Gleason grade of any cancer identified was noted.
Patients with Gleason grade 3 1 4 carcinoma or less were
considered well differentiated and those with Gleason grade
4 1 3 carcinoma or higher were considered poorly differenti-
ated.9
Patients found to have prostate cancer underwent complete
clinical staging, including uniform use of bone scintigraphy in
all cases. Following initiation of their choice of treatment,
patients returned for clinic visits with physical examination
and PSA level every 3 to 6 months at either the Palo Alto
facility or another Veterans Affairs (VA) facility sharing the
VISTA (Veteran’s Health Information Systems and Technol-
ogy Architecture, Department of Veterans Affairs, Technical
Services) network through which patients could be followed.
Progression of disease was considered three serial rising PSA
levels after post-treatment nadir.10 For patients on expectant
management, three serial PSA rises after diagnosis were used.
Those patients without prostate cancer were followed with
physical examination and PSA level every 6 to 12 months. All
patients were followed for a mean of 52.9 months and median
of 58 months (range 34 to 69). Date and cause of death were
determined according to documentation in the VISTA system.
Patients were divided into three age groups for analysis: (1)
70 to 74-year-old group (n 5 132), (2) 75 to 79-year-old
group (n 5 57), and (3) 80-year-old and older group (n 5 21).
As shown in Table I, in the 70 to 74-year-old group, the mean
age was 72 years, the PSA levels ranged from 0.4 to 564 ng/mL
(median 9.1), and an average of 8 biopsies were performed per
patient (range 6 to 13). In the 75 to 79-year-old group, the
mean age was 76 years, the PSA levels ranged from 1.9 to 120
ng/mL (median 8.2), and an average of 8 biopsies were per-
formed per patient (range 6 to 12). In the 80-year-old and
older group, the mean age was 83 years, the PSA levels ranged
from 3.4 to 360 ng/mL (median 17.7), and an average of 7
biopsies were performed per patient (range 6 to 10).
Tests for correlation were performed with the Spearman’s
rank correlation; these correlations were tested for statistical
significance by the Mann-Whitney U test. Evaluations for sta-
tistically significant differences between unpaired groups were
performed with the Student’s unpaired two-tailed t test.
RESULTS
In the 210 patients aged 70 years and older re-
ferred for transrectal ultrasound and biopsies, can-
cer was found in 120 (56.8%). As shown in Table I,
the cancer detection rate was significantly higher
in the 80-year-old and older age group, with cancer
detected in 17 (81.0%) of the 21 patients, com-
pared with the 70 to 74-year-old group (cancer in
75 of 132 patients or 56.8%) and the 75 to 79-year-
old group (cancer in 28 of 57 patients or 49.1%).
Table I shows that of the 75 prostate cancer pa-
tients aged 70 to 74 years, 50 (66.7%) had well-
differentiated prostate cancer (grade 3 1 4 or less)
and 25 (33.3%) had poorly differentiated cancer
(grade 4 1 3 or higher). Similarly, in the 28 pa-
tients aged 75 to 79 years with prostate cancer, 19
(67.9%) had well-differentiated tumors and 9
(32.1%) had poorly differentiated tumors. How-
ever, there was an inverse distribution of grade in
the 17 prostate cancer patients aged 80 years and
older compared with the younger age groups, with
only 6 (35.3%) having well-differentiated cancers
and 11 (64.7%) having poorly differentiated tu-
mors. There was a significant positive correlation
between increasing age and increasing grade (r 5
0.4, P ,0.0005).
Of the 210 patients aged 70 years and older re-
ferred for transrectal ultrasound and biopsy, 41
(19.4%) died within the 2 to 5-year follow-up pe-
riod (Table I); only 3 (1.4%) died of complications
of their prostate cancer. In the 41 patients who
died, their death was an average of 25 months after
biopsy (range 3 to 50). Of the 91 patients who
underwent prostate ultrasound-guided biopsy but
were found to have no cancer, 18 (19.8%) died
during the follow-up period. Of the 120 found to
have prostate cancer, 23 (19.2%) died during the
follow-up period; 3 (2.5%) died of prostate cancer.
This difference was not statistically significant. In
the older, 80 years and older, age group, 6 (28.6%)
of 21 patients died between 6 and 37 months
(mean 23.2) after biopsy. In the 75 to 79-year-old
group, 14 (24.6%) of 57 patients died between 4
and 50 months (mean 27.8) after biopsy. Of the
132 patients in the 70 to 74-year-old group, 21
(15.9%) died between 2 and 39 months (mean 23)
after biopsy. No significant difference was seen in
the death rate or the time passage between the bi-
opsy procedure and death in any of the three age
groups when all patients (both those with and
without a diagnosis of cancer) are considered.
However, when only the patients with cancer are
considered, there was a trend toward increasing
death rate with increasing age. There was an over-
all death rate of 16% and a 1.3% prostate cancer-
specific death rate for the 70 to 74-year-old cancer
patients, 21.4% overall and 7.1% prostate cancer-
specific death rate for the 75 to 79-year-old pros-
tate cancer patients, and 29.4% overall and 0%
prostate cancer-specific death rate for the 80-year-
old and older prostate cancer patients (Table I).
As expected, the cancer detection rate increased
with increasing PSA (Table II); the prostate cancer-
specific death rates also increased with increasing
PSA in patients younger than 80 years of age, but
patients aged 80 years and older died of other
causes regardless of PSA at presentation. Similarly,
the cancer detection rate increased with increas-
ingly suspicious digital rectal examination (Table
III); the prostate cancer-specific death rate in-
creased with worsening rectal examination find-
ings in the patients younger than 80 years of age,
296 UROLOGY 56 (2), 2000
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however, patients aged 80 years or older died of
noncancer causes regardless of the stage of disease
at the time of presentation. Also seen in Table III,
22 (18.3%) of the 120 cancer patients were local
Stage T1, 76 (63.3%) were local Stage T2, and 24
(20.0%) had local Stage T3 prostate cancer. Fur-
ther staging evaluation revealed that 10 (8.3%) of
the 120 prostate cancer patients had metastatic dis-
ease. The proportion of patients with locally ad-
vanced or metastatic disease increased with increas-
ing age (Table III). A significant positive correlation
existed between increasing age and increasing stage
(r 5 0.3, P ,0.0005).
Of the 120 patients aged 70 years and older
found to have prostate cancer, 9 (7.5%) elected to
undergo radical prostatectomy (Table IV). One of
these 9 patients choosing radical prostatectomy
had biochemical failure 32 months following sur-
gery. There were 82 (68.3%) of the 120 prostate
cancer patients who chose hormonal therapy, of
which 36 (43.9%) of the 82 patients eventually
demonstrated progression as measured by a rising
PSA during a mean follow-up of 39.5 months.
Twenty-two (18.3%) patients chose expectant
management of which 8 (36.4%) progressed dur-
ing a mean follow-up of 46.8 months. Seven (5.8%)
chose external beam radiation therapy of which 2
(28.6%) progressed during a mean follow-up of
35.5 months. No statistically significant difference
was seen in the incidence of PSA failure in the
patients choosing expectant management between
the 70 to 74-year-old group and the 75 to 79-year-
old group, nor was there a difference in the inci-
dence of PSA failure in the patients choosing hor-
monal therapy between these two age groups. The
incidence of biochemical progression during ex-
pectant management in the 70 to 74-year-old
group was 30.0% and in the 75 to 79-year-old
group was 33.3%. In patients undergoing hor-
monal therapy, the PSA failure rate was 25.5% in
the 70 to 74-year-old group and 27.8% in the 75 to
79-year-old group. In contrast, the 80-year-old and
older group had a PSA failure rate of 53.8% for
hormonal therapy; this finding was a statistically
significant difference from the other two age
groups (P 5 0.04). The 80-year-old and older pa-
tients who chose expectant management also had a
substantially higher PSA failure rate of 66.7%,
compared with the younger age groups, although
this difference did not reach statistical significance.
COMMENT
We found a higher incidence of prostate cancer,
grade, and stage with increasing age as well as a
poorer response to therapy. Other authors have
observed similar trends. In a large study of nearly
5000 prostate cancer patients, Borek et al.11 found
that 22.2% of patients younger than age 60 years
had poorly differentiated cancer compared with
32.5% for patients aged 80 years and older. In a
series of 350 radical prostatectomy specimens,
Kabalin et al.12 found that 75% of patients older
than 70 years had Gleason grade 4 and/or 5 tumor
compared with 62% of those 61 to 70 years old,
54% in the 51 to 60-year-old group, and 35% in
those aged 41 to 50 years. In another series based
on patients diagnosed as part of a large PSA screen-
ing program, Richie et al.13 found that the cancer
was organ confined in 74% of patients younger
than age 60 years and in 60% of men older than 70
years of age. Such trends persist even when only
the most favorable population is considered.
Carter et al.,14 in a study of 492 men with clinical
Stage T1C disease who underwent radical prosta-
tectomy, found that age was a strong predictor of
whether or not the cancer was surgically curable
on the basis of pathologic findings in the surgical
specimens. Similarly, O¨bek et al.15 have docu-
mented a higher biochemical failure rate in 41 pa-
tients older than age 70 years who underwent rad-
ical prostatectomy compared with 460 patients
aged 70 years and younger (27% versus 13%), as
well as a shorter time until failure (median of 48
months versus median of 60 months). In addition
to cancer control concerns, complications of ther-
apy are potentially more dramatic in the older pop-
ulation. Catalona et al.16 have shown that the com-
plications of impotence and incontinence are more
common in patients aged 70 years and older. Lu-
Yao et al.17 in a recent review of more than 100,000
patients via Medicare claims found that the 30-day
surgical mortality rate following radical prostatec-
tomy for patients between the ages of 65 and 69
years was less than 0.5%, whereas the surgical mor-
tality rate for patients aged 70 years and older ap-
proached 1%.
Not all authors agree that older patients will have
a less favorable outcome. Corral and Bahnson18 re-
viewed 101 men aged 70 to 79 years with prostate
cancer with a mean follow-up of 59 months and
compared the 43% who underwent radical prosta-
tectomy with the 57% who were treated with hor-
monal therapy, radiation therapy, or expectant
management. In their study, survival for the surgi-
cally treated group was significantly better than for
the medically treated group. They concluded that
men undergoing radical prostatectomy at their insti-
tution in the eighth decade of life did not frequently
die of intercurrent disease and experienced accept-
able morbidity and mortality. Similarly, Huguenin
et al.19 recently showed no difference in the dis-
ease-free survival of men older than 74 years of age
treated with radiation therapy for their prostate
cancer when compared with matched younger pa-
tients. Pow-Sang et al.,20 in a longitudinal study of
298 UROLOGY 56 (2), 2000
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30 high-grade, Stage IV prostate cancer patients
aged 80 years or older, found that survival at 3
years was 60%, which was slightly better than pa-
tients with similar stage cancer 10 years younger
(57.8%).
The patient population in our study may not rep-
resent the more advanced nature of prostate cancer
in older patients but rather the hesitance of refer-
ring urologists to diagnose low-grade, low-stage
prostate cancer in older patients in whom the dis-
ease will have no impact on their quantity and
quality of life. Many urologists, as well as primary
care providers, may appropriately follow elderly,
asymptomatic men with expectant management
for elevated PSA levels or with digital rectal exam-
ination abnormalities, possibly a result of prostate
cancer, for which a tissue diagnosis is never made.
Neither our study nor a review of the literature
clearly defined how aggressive urologists should be
for these elderly men. It is generally accepted that
screening and aggressive case finding to seek out
early, organ-confined disease is contraindicated in
those with a life expectation less than 10 years,3 but
how does the urologist confirm an individual’s life
expectancy or exclude advanced disease without
investigation?
In a study of participants in the Canada Health
Survey, Eapen et al.21 found that, for prostate can-
cer patients aged 80 years and older, comorbidity
was not a significant predictor of survival. Those
researchers admonished against restricting access
to PSA screening on the basis of survival probabil-
ity in elderly patients. Roche et al.22 agree that age
alone is a poor predictor of survival and an inap-
propriate factor by which to exclude patients from
screening and clinical trials for cancer treatment.
They proposed a formal geriatric assessment, in-
cluding measures of cognitive, functional, and af-
fective status in elderly patients being considered
for intervention. Perhaps the most critical of cur-
rent approaches to prostate cancer in the elderly is
a review of several centers by Bennett et al.23 that
showed that patients aged 75 years and older had
significantly less intensive clinical staging evalua-
tions and discussion of treatment options when
compared with patients aged 50 to 65 years. Green-
field et al.24 have noted similar results in studies of
elderly patients with other malignancies and have
suggested the presence of widespread age bias in
cancer diagnosis, staging, and treatment. Saltzstein
et al.,25 in an exhaustive review of more than
14,000 cancer patients older than 90 years of age
from the California Cancer Registry, showed that
patients older than 90 years of age were diagnosed
with cancer at a more advanced stage and received
a more abbreviated staging evaluation. Those pa-
tients that died, however, usually died of causes
other than their cancer.25
It is, unfortunately, difficult if not impossible to
conduct completely objective discussions of treat-
ment options, particularly with prostate cancer.
For example, with asymptomatic, organ-confined
prostate cancer, expectant management would be
encouraged, and radical prostatectomy would cer-
tainly not be presented with enthusiasm as a rea-
sonable option to patients aged 80 years and older,
whereas the benefits of surgery and other treat-
ments with curative intent would be strongly rec-
ommended to younger patients.
CONCLUSIONS
In a review of prostate cancer in the elderly by
Kirk,3 he stated, “The aim always is diagnosis
where appropriate, treatment which will be of ben-
efit, and quality rather than length of life.” While
seemingly simple, following these elusive caveats
remains a challenge as the population ages, longev-
ity increases, and prostate cancer therapies evolve.
We discourage screening in asymptomatic el-
derly and/or debilitated (life expectancy estimated
at less than 10 years) patients. Should an asymp-
tomatic man with a modest PSA elevation (less
than 20 ng/mL) and/or with digital rectal examina-
tion abnormality present as a referral for prostate
biopsy, we counsel the patient on the low potential
of prostate cancer affecting his life expectancy or
quality of life as well as the possibility that proce-
dures performed to pursue cancer diagnosis as well
as subsequent treatment could significantly affect
his quality of life. The final decision, however, re-
mains with the patient.
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